Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Brii Biosciences Limited currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a highly concentrated prosecution focus. The lack of dispersion across multiple examiners suggests a streamlined interaction with the patent office for this specific portfolio. Practitioners can focus their strategy on a single set of examiner preferences rather than navigating diverse art unit standards.
The busiest examiner for the company is CHESTNUT, BARRY A, who is responsible for 1 pending office action. This represents the entirety of the company's current pending workload. For a practitioner, this means that the outcome of the portfolio's current prosecution phase rests entirely on the decisions of a single examiner within a single art unit. The 1 to 1 ratio between pending actions and distinct examiners ensures that the official is not overwhelmed by the company's filings, potentially allowing for more focused attention on the individual application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18883612 | IMMUNOGENIC COMPOSITIONS FOR TREATMENT OF HEPATITIS B | CHESTNUT, BARRY A | 1672 | DP | Non-Final OA | — | Pending | Sep 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBrii Biosciences Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Barry A Chestnut has the most, with 1 of Brii Biosciences Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.